An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

Defining ESG can sometimes be straightforward: it’s a finance and investing approach centered on managing risks related to ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Eli Lilly And Co (LLY) stock saw a decline, ending the day at $912.75 which represents a decrease of $-33.56 or -3.55% from the prior close of $946.31. The stock opened at $941.16 and touched a low of ...

Shares of Viking Therapeutics VKTX have more than tripled in market value in the past year. The upside was triggered by ...